News ImmunityBio bags elusive label extension for Anktiva The FDA has handed ImmunityBio a key label extension for bladder cancer therapy Anktiva, giving it a leg-up on rival drug Inlexzo from J&J.
News Expanded US Imaavy approval first ever for wAIHA The FDA has approved Johnson & Johnson's Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune haemolytic anaemia (wAIHA).
News J&J scores EU approval for Tecvayli combo in second line Johnson & Johnson's multiple myeloma regimen is now approved as a second line treatment in both the US and the EU.
News Cavanaugh to replace Taubert as J&J's pharma head Jennifer Taubert will hand over the reins of Johnson & Johnson's Innovative Medicines division to Tom Cavanaugh after she retires on 1st September.
News J&J takes $2.58bn option to buy in vivo CAR-T firm Sail Johnson & Johnson has bid for a slice of the in vivo CAR-T category, signing an alliance with Sail Bio that could evolve into a $2.58bn takeover.
News Is J&J approaching the end of its talc litigation hangover? Johnson & Johnson has made a $5.5bn bid to finally bring more than 15 years of litigation over the safety of its talcum powder products to a close.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.